Further tests are conducted on tumor samples using various pathological diagnosis methods such as immunohistochemistry (IHC) and molecular profiling methods such as transcriptomics, proteomics, and genomics [37,49,50], including assessments for the combined loss of chromosome arms 1p and 19q, mutations and/or the expression of p53, the presence of isocitrate dehydrogenase 1 (IDH1) mutation (commonly within exon 4 to codon 132, with the most frequent being c.395 G>A (R132H) substitutions) [51], and epigenetic modifications such as MGMT hypermethylation [29]. The gene discussed is TP53; the disease is neoplasm.